IGF-1 LR3: what it is, how it works and what the studies show

Summary

IGF-1 LR3 carries the R3 substitution (arginine at position 3) and an N-terminal “Long” extension, so that binding to the IGFBPs is reduced and availability for activating the IGF-1R receptor is increased. The result is a more prolonged biological action than “standard” IGF-1 and a useful tool in anabolism/recovery models. The product is not intended for human use.

What IGF-1 is and what differentiates IGF-1 LR3

IGF-1 is a peptide hormone produced mainly in the liver under the influence of GH, acting endocrinally/paracrinally on many tissues. It binds to the IGF-1R receptor and activates cascades related to cell growth, differentiation, protein synthesis, glucose transport and tissue remodelling.

• R3: substitution with arginine at position 3 → reduced affinity for IGFBP → a larger proportion of “free” IGF-1.
• Long: N-terminal extension → further reduction of binding to the IGFBPs → prolonged functional activity compared with IGF-1.

In practice: higher and more prolonged availability in tissues expressing IGF-1R; popular for in vitro/in vivo models of anabolism & regeneration.

Mechanism of action & key pathways

IGF-1 LR3 binds to the IGF-1R receptor (tyrosine kinase) and mainly activates:

• PI3K/Akt/mTOR: protein synthesis, cell survival, inhibition of proteolysis, glucose regulation.
• RAS/RAF/MEK/ERK (MAPK): cell proliferation/differentiation and tissue remodelling.

In skeletal muscle: activation of satellite cells, ↑ myofibrillar protein synthesis, ↓ proteolysis, support of recovery after mechanical stress. In connective tissue (tendons/ligaments): preclinical data show faster remodelling; in epithelial tissues: support of wound healing. Projections from animal/cell models do not automatically translate to humans without approved indications.

Possible benefits (research context)

• Anabolic effect & body composition: scenarios of ↑/maintenance of lean mass under catabolic stress (caloric restriction, large training volumes).
• Muscle & tendon recovery: a favourable effect on collagen expression/proliferation in tendon tissues; in muscle, support of regeneration after microtrauma.
• Wound healing: acceleration of epithelialisation/granulation in preclinical models.
• Metabolic effects: improved glucose uptake in myocytes (insulin-like signalling) — possible drop in blood glucose; see the risks.

The above are hypotheses/observations in a research setting and do not constitute medical indications.

Risks & adverse effects (why a conservative approach is required)

• Hypoglycaemia: due to insulin-like actions; ↑ risk with low carbohydrates/skipped meals/other insulinogenic agents (symptoms: weakness, tremor, sweating, confusion).
• Fluid retention/oedema, headache, joint/muscle pain: associated with anabolic/proliferative pathways and water-electrolyte changes.
• Potential mitogenic “pressure”: IGF-1R signalling is proliferative — active/unclarified neoplasms = absolute contraindication.
• Paradoxical insulin resistance: chronic/inappropriate exposure may burden metabolism in predisposed individuals.
• Anti-doping/regulatory: manipulations of the GH/IGF-1 axis fall under WADA prohibitions; see the WADA List.

IGF-1 LR3 vs. GH secretagogues & Somatropin

• Versus GH secretagogues (GHRH analogues, ghrelin agonists): secretagogues enhance endogenous GH pulses → secondarily ↑ IGF-1 within physiological limits. IGF-1 LR3 acts “downstream”, directly on IGF-1R, without depending on the pulsatility of GH.
• Versus Somatropin (exogenous GH): GH increases IGF-1 via the liver/tissues, with systemic actions and a different risk profile; IGF-1 LR3 “bypasses” GH and activates IGF-1R directly — useful for isolating the role of IGF-1 compared with GH.

Who/when would choose it (research rationale)

• Focus on local regeneration & anabolism: models that isolate the direct action of IGF-1R in muscle/connective tissue from GH-dependent processes.
• Metabolic hypotheses: study of glucose transport, insulin-like signals and mTOR regulation under different nutritional scenarios.
• Specific tissue experiments: in vitro in myoblasts/fibroblasts/tenocytes for proliferation/differentiation & matrix.

In a clinical context for humans it is not approved and use is not recommended.

Combinations (research context – principles, not recommendations)

• With GH secretagogues (e.g. CJC-1295 without DAC + Ipamorelin): for comparison of the “physiological” GH→IGF-1 axis versus “direct” activation of IGF-1R. Simultaneous exposure may over-enhance signalling → a conservative design is required.
• Redox support (e.g. Glutathione): to limit oxidative stress under high mechanical/training load on tissues.
• Nutritional protocols: the IGF signal is subject to the availability of amino acids/energy — without sufficient substrate, the anabolic impact is limited.
• Combinations with increased risk: exogenous GH, insulin or strong insulinogenic stimuli → ↑ risk of hypoglycaemia/excessive IGF activity.

Practical notes for protocols (educational)

• Form & stability: IGF-1 LR3 is supplied as a lyophilised powder for research use. Ready-made liquids have limited stability outside the cold chain; the lyophilised form offers flexibility until reconstitution.
• Timing vs. feeding/loading: in the models a dependence on nutritional status (amino acids) and mechanotransduction (training stimulus) is observed.
• Monitoring: glucose, signs of fluid retention/headache, changes in appetite/behaviour. In a human clinical setting, IGF-1/IGFBP profiles would be required — the product is not for human use.
• Local vs. systemic approach: even local exposure may have systemic consequences depending on bioavailability/protocol.

When it is NOT used / warnings

• Active/unclarified neoplasms — IGF-1R is a mitogenic pathway.
• History of proliferative diseases without medical supervision.
• Severe cardiometabolic diseases, insulin resistance/dysglycaemia.
• Pregnancy/lactation, minors.
• Athletes: WADA anti-doping regulations.
• Outside ethical/regulatory frameworks — for research use only.

Place of IGF-1 LR3 in the “Recovery and anabolic peptides” category

The category includes agents that either regulate the GH–IGF-1 axis (e.g. GHRH analogues such as CJC-1295 without DAC, Sermorelin; ghrelin agonists such as Ipamorelin; the metabolically targeted Tesamorelin), or support recovery through other mechanisms (e.g. Glutathione). IGF-1 LR3 is a “downstream” tool — it activates the receptor directly and allows the study of specific IGF actions independently of GH pulsatility.

• Focus on sleep/recovery: CJC-1295 without DAC + Ipamorelin are often preferred.
• Visceral fat/metabolism: Tesamorelin has strong data in specific populations.
• Direct IGF-1R action in muscle/connective tissue: IGF-1 LR3 is a logical research tool — with clear risks.

See the category IGF-1 LR3 product

Sources (indicative)

1. WADA – Prohibited List (GH/IGF-1 interventions and anti-doping regulations).
2. PubMed – IGF-1 receptor signaling review (query) (theoretical basis of IGF-1R signalling).
3. PubMed – IGF-1 & skeletal muscle hypertrophy (query) (muscle/hypertrophy/satellite cells).
4. PubMed – IGF-1 & wound healing (query) (healing/epithelialisation).